Cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation: Significant progress, but many unresolved problems

Expert Opinion on Biological Therapy

Volumn 9, Issue 4, 2009, Pages 383-385

  Busca, Alessandro ^a  

^a Bone Marrow Transplant Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; CALCINEURIN INHIBITOR; CIDOFOVIR; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; VALGANCICLOVIR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG MECHANISM; DRUG WITHDRAWAL; EDITORIAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; METABOLIC DISORDER; NEPHROTOXICITY; NEUTROPENIA; TASTE DISORDER; THROMBOCYTOPENIA; VACCINATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; POSTOPERATIVE COMPLICATIONS;

CYTOMEGALOVIRUS;

EID: 67649295518     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902854448     Document Type: Editorial

References (16)

1. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009;43(4):275-291
2. Gerna G, Lilleri D, Caldera D, et al. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008;41(10):873-879 (Pubitemid 351766594)
3. Ljungman P, de la Camara R, Cordonnier C, et al. European Conference on Infections in Leukemia. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008;42(4):227-240
4. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118(3):173-178 (Pubitemid 23034801)
5. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99(4):1159-1164 (Pubitemid 34547067)
6. Takenaka K, Eto T, Nagafuji K, et al. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2009: published online: 17 January 2009, doi: 10.1007/s12185-008-0249-252
7. Busca A, de Fabritiis P, Ghisetti V, et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 2007;9(2):102-107 (Pubitemid 46669078)
8. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9(9):543-558 (Pubitemid 38351787)
9. Lilleri D, Gerna G, Furione M, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood 2007;110(7):2757-2760 (Pubitemid 47523202)
10. Allice T, Busca A, Locatelli F, et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009;63(3):600-608
11. Winston DJ, Young JA, Pullarkat V, et al. prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111(11):5403-5410
12. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992;257:238-241
13. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005;202:379-386 (Pubitemid 41126955)
14. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002;99:3916-3922 (Pubitemid 35332029)
15. Micklethwaite K, Hansen A, Foster A, et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:707-714 (Pubitemid 46767999)
16. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003;362:1375-1377 (Pubitemid 37338339)